Results 21 to 30 of about 234,795 (273)

Stigmatization among Patients with Plaque Psoriasis

Journal of Clinical Medicine, 2023
The aim of the study was to analyze the level of stigmatization among patients with plaque psoriasis according to their demographic and clinical characteristics. The study included 122 patients who completed the 6-item and 33-item Feelings of Stigmatization Questionnaire and a sociodemographic survey.
Barbara Jankowiak, Elżbieta Krajewska-Kułak, Marta Jakoniuk, Dzmitry F. Khvorik   +3 more
openaire   +3 more sources

Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy [PDF]

, 2008
Molluscum contagiosum is a common viral skin infection in children with atopic diathesis and not rare in HIV patients. We report a 45-year-old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab.
Flaig, Michael J., Prinz, Jörg Christoph, Weisenseel, Peter, Kuznetsov, Alexander Vasilevic, Michael Flaig, Jörg Christoph Prinz, Peter Weisenseel, Alexander Vasilevic Kuznetsov   +7 more
core   +1 more source

Secukinumab for plaque psoriasis

Medwave, 2018
Biological treatments have appeared as the main alternative for the management of patients with plaque psoriasis that do not respond to conventional treatment. So, evaluating its actual efficacy and safety is needed.We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information ...
Gonzalo Ordenes-Cavieres, Romina Andino-Navarrete   +1 more
openaire   +4 more sources

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo [PDF]

, 2012
We have previously shown that peroxisome proliferator activating receptor ß/d (PPAR ß/d is overexpressed in psoriasis. PPAR ß/d is not present in adult epidermis of mice.
Kevin D. Read (165019), Palmer Colin, Kally Booth, Katrin Hack, Booth Kally, Colin Palmer (165015), Suzanne Norval, Read, Kevin D, Hack Katrin, John Foerster (165047), Robert Kime, Kevin D Read, John Foerster, Kally Booth (165039), Louise Reilly, Suzanne Norval (165024), Read Kevin D., Palmer, Colin; id_orcid, Norval, Suzanne, Reilly, Louise, Louise Reilly (165006), Reilly Louise, Read, Kevin, Palmer, Colin, Hack, Katrin, Robert Kime (165030), Colin Palmer, Kime Robert, Foerster John, Foerster, John, Katrin Hack (165002), Kime, Robert, Norval Suzanne, Booth, Kally   +33 more
core   +1 more source

Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring

Indian Dermatology Online Journal, 2016
On the basis of current evidence derived from hospital-based studies, mostly from North India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%, with a much lower prevalence in children.
Sunil Dogra, Rahul Mahajan
doaj   +1 more source

Health-related quality of life in patients with palmoplantar pustulosis – a Swedish register study

Annals of Medicine
Background Real-world data on health-related quality of life (HRQoL) in palmoplantar pustulosis (PPP) are scarce and few studies have analysed the generic HRQoL.Objectives To assess HRQoL using the generic EQ-5D instrument and the Dermatology Life ...
Jenny M. Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf   +2 more
doaj   +1 more source

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab [PDF]

, 2017
Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine ...
Tessa L Hanley, Hanley, Tessa L, Yiu ZZN, Hanley TL, Zenas ZN Yiu, Yiu, Zenas Zn; id_orcid   +5 more
core   +1 more source

Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis

Journal of International Medical Research, 2019
Background Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis.
Fangyuan Tian, Zhaoyan Chen, Ting Xu
doaj   +1 more source

Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol

BMJ Open, 2020
Introduction Psoriasis is a life-long, immune-mediated disease that greatly reduces the quality of life of patients. Plaque psoriasis is the most common form of psoriasis. Treatment options for plaque psoriasis with good tolerance and sufficient response
Qi Wang, Lin Cai, Qian Wang, Wenliang Dong, Xiaoyan Nie, Jiaxue Wang, Lin Xia, Weixing Fu, Tiantian Shen, Huaying Fan, Suping Niu, Yimin Cui, Qingshan Zheng, Jianzhong Zhang, Yi Fang   +14 more
doaj   +1 more source